Vetter and Sentry BioPharma establish preferred partnership agreement

Article

Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis.

Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis. According to a statement, the collaboration will "help streamline the path of study drugs from filling laboratory to clinic while safeguarding product integrity".

"Our partnership with Sentry affirms our mutual commitment to helping clients get high-quality products to market quickly and efficiently," said Peter Soelkner, Managing Director of Vetter. "It also affirms Vetter’s commitment to the North American market."

The Chicago facility, which focuses on preclinical to phase II projects, is Vetter’s first facility outside of Germany and is an expansion of Vetter Development Service. It will be operational at the beginning of Q4 2010.

"We’re proud to partner with Vetter," said Jennifer Marcum, CEO of Sentry BioPharma Services. "Both of our companies share the same dedication to the quality and safety of our clients’ products."

www.vetter-pharma.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content